NVNO | enVVeno Medical Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.03 - 3.21
52 Week Range	2.4500 - 6.97
Beta	1.40
Implied Volatility	409.96%
IV Rank	35.51%
Day's Volume	135,200
Average Volume	145,472
Shares Outstanding	17,536,000
Market Cap	53,134,080
Sector	Healthcare
Industry	Medical - Devices
IPO Date	2018-05-31

Valuation
Profitability
Growth
Health
P/E Ratio	-2.35
Forward P/E Ratio	N/A
EPS	-1.29
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	31
Country	USA
Website	NVNO

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

NVNO's peers: MODD, CODX, ECOR, ICAD, IRIX, MYO, NSYS, AZYO, AIMD, SRDX, LNSR, RXST, AXGN, TMCI, LUNG, OFIX, PETV, TLIS, TNON, SSKN, SIEN, OSA, LIVN, ELMD, KIDS, SRTS

*Chart delayed

Analyzing fundamentals for NVNO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see NVNO Fundamentals page.

Watching at NVNO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NVNO Technicals page.